BioSpace News Archive

Curavit Clinical Research, a virtual contract research organization (VCRO), has been selected by digital therapeutics company, Swing Therapeutics, to be a virtual site for its pivotal trial of an investigational digital therapeutic (DTx) for fibromyalgia.

Company CEO Kurt Azarbarzin to participate in panel discussion on emerging trends in robotic platforms and will provide an update on development of the Endoluminal Surgical System.

Collagen Matrix, Inc., a leader in regenerative medicine, global manufacturer of collagen and other biomaterial-based medical devices, and Linden Capital Partners portfolio company (“Collagen Matrix” or “the Company”), announced today its 510(k) Clearance for a new Fibrillar Collagen Wound Dressing.

Combines NewAmsterdam’s lead clinical program obicetrapib with Menarini’s deep cardiovascular disease and regional expertise.

Dermavant Sciences, today announced that new data from the one-year safety and efficacy final analyses of the Phase 3 PSOARING 3 long-term, open-label extension (“LTE”) study of VTAMA® (tapinarof) Cream, 1% for the treatment of plaque psoriasis in adults was published in the Journal of the American Academy of Dermatology (JAAD) on June 26, 2022.

ENDRA Life Sciences Enhances TAEUS ® System Intellectual Property Portfolio with Issuance of 28th U.S. Patent.

Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer.

NYU Langone Fertility Center, a member of Inception Fertility’s network of clinical practices, in conjunction with NYU Grossman School of Medicine, released the largest U.S. report of elective fertility preservation outcomes to date.

Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership team and scientific advisory board and completed a Series B funding round.

The Centre for Probe Development and Commercialization has licensed [18F]PSMA-1007 from ABX- advanced biochemical compounds GmbH and will hold the exclusive license to manufacture, commercialize and distribute the imaging agent in Canada.